Efficacy and safety of semaglutide and tirzepatide in the therapy of obesity and type 2 diabetes – current state of knowledge
DOI:
https://doi.org/10.12775/QS.2026.70.74691Keywords
semaglutide, tirzepatide, obesity, type 2 diabetes mellitus, diabesityAbstract
Background. The diabesity epidemic (obesity and type 2 diabetes) requires a shift from a glucocentric to a holistic approach, making weight reduction a clinical goal equal to glycemic control. Incretin-based therapies (semaglutide, tirzepatide) represent a breakthrough due to their pleiotropic effects.
Aim. This study analyzes their efficacy, safety, molecular mechanisms, and cardio/nephroprotection in light of recent trials and guidelines.
Material and methods. PubMed and Google Scholar were searched (2018–2026) using MeSH terms: obesity, type 2 diabetes, GLP-1/GIP agonists. The analysis included phase III trials (STEP, SURPASS, SURMOUNT), meta-analyses, and guidelines of the Polish Diabetes Association (PTD 2026), the Polish Association for the Study of Obesity (PTLO 2024), and the American Diabetes Association (ADA). Case reports and early-phase studies were excluded.
Results. Diabesity is linked to an incretin deficit. GLP-1 and dual GIP/GLP-1 receptor agonists mimic the incretin effect, modulating appetite and enhancing insulin sensitivity. This facilitates sustained weight loss and multi-organ protection. Evidence from STEP and SURPASS trials highlights robust cardioprotection, nephroprotection, and reduced hepatic steatosis in MASLD. By targeting cerebral reward centers, these agents address hedonic hunger, improving long-term metabolic health.
Conclusions. Incretin therapy is revolutionizing treatment. Semaglutide and tirzepatide achieve high weight reduction (>20%) and lower the risk of MACE, renal failure, and hepatic steatosis. Latest PTD (2026) and PTLO (2024) guidelines recommend their early implementation in primary care to combat obesity and its complications.
References
1. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223. https://doi.org/10.1038/s41573-021-00337-8.
2. Bogdański P, Michałowska J. The role of incretin hormones and drugs in the therapy of obesity and selected metabolic disorders. Forum Zaburzeń Metabolicznych. 2021;12(2):61-69. https://journals.viamedica.pl/forum_leczenia_otylosci/article/view/84657 (access: 2026.04.21). [Polish].
3. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, American Diabetes Association. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S128-S139. https://doi.org/10.2337/dc23-S008.
4. Bąk-Sosnowska M, Białkowska M, Bogdański P, Chomiuk T, Dobrowolski P, Gałązka-Sobotka M, Holecki M, Jankowska-Zduńczyk A, Jarosińska A, Jezierska M, Kamiński P, Kłoda K, Kręgielska-Narożna M, Kuryłowicz A, Lech M, Major P, Mamcarz A, Mastalerz-Migas A, Matyjaszek-Matuszek B, Ostrowska L, Piwońska-Solska B, Płaczkiewicz-Jankowska E, Prejbisz A, Stachowska E, Stelmach-Mardas M, Szeliga J, Szulińska M, Tarnowski W, Tomasiewicz K, Tomasik T, Tomiak E, Walczak M, Wyleżoł M, Żak-Gołąb A. Clinical recommendations for the management of patients with obesity 2024 – Statement of the Polish Association for the Treatment of Obesity. Med Prakt. 2024;(special ed.):1-80. https://www.mp.pl/nadwaga-i-otylosc/wytyczne/366123,zalecenia-kliniczne-dotyczace-postepowania-u-chorych-na-otylosc-2024 (access: 2026.04.21). [Polish].
5. Olszanecka-Glinianowicz M, Dudek D, Filipiak KJ, Krzystanek M, Markuszewski L, Ruchała M, Tomiak E. Treatment of overweight and obesity during and after a pandemic. Let’s not wait for the development of complications – new guidelines for doctors. Psychiatr Pol. 2020;54(6):1263-1268. https://doi.org/10.12740/PP/130768.
6. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102.
7. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. https://doi.org/10.2337/dci22-0034.
8. Araszkiewicz A, Borys S, Broncel M, Budzyński A, Cyganek K, Cypryk K, Cyranka K, Czupryniak L, Dąbrowski M, Dzida G, Dziedzic T, Franek E, Gajewska D, Gawrecki A, Górska M, Gumprecht J, Idzior-Waluś B, Jarosz-Chobot P, Kalarus Z, Karczewska-Kupczewska M, Klupa T, Kokoszka A, Korzon-Burakowska A, Kowalska I, Krętowski A, Kwiendacz H, Majkowska L, Małecki M, Mamcarz A, Matejko B, Matyjaszek-Matuszek B, Mianowska B, Mrozikiewicz-Rakowska B, Myśliwiec M, Nabrdalik K, Narkiewicz K, Sieradzki J, Skupień J, Solnica B, Stompór T, Strojek K, Szadkowska A, Szypowska A, Wender-Ożegowska E, Witek P, Wolnik B, Wyleżoł M, Wylęgała E, Zmysłowska A, Zozulińska-Ziółkiewicz D, Szewczyk M, Wolf J, Szczeklik W, Studzińska D, Marcinkiewicz A, Walusiak-Skorupa J, Górska R. 2026 Guidelines on the management of patients with diabetes. Position statement of the Polish Diabetes Association. Curr Top Diabetes. 2026;6(1):1-134. https://ptdiab.pl/zalecenia-ptd/zalecenia-kliniczne-dotyczace-postepowania-u-osob-z-cukrzyca-2026 (access: 2026.04.21). [Polish].
9. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, Baeres FM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R, for the FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. https://doi.org/10.1056/NEJMoa2403347.
10. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH, for the SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563.
11. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785. https://doi.org/10.1016/S2213-8587(19)30249-9.
12. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. https://doi.org/10.3389/fendo.2019.00155.
13. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, for the SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-220. https://doi.org/10.1056/NEJMoa2206038.
14. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. https://doi.org/10.1016/j.cmet.2018.03.001.
15. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito HR, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski DM, Wolf D, Petrie MC, for the STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. https://doi.org/10.1056/NEJMoa2306963.
16. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, for the SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519.
17. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, for the STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183.
18. Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409-418. https://doi.org/10.1016/j.diabet.2018.12.001.
19. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, for the STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2); a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. https://doi.org/10.1016/S0140-6736(21)00213-0.
20. Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4.
21. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Landó LF, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736(21)01324-6.
22. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang_ Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ, on behalf of the SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, paralel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7.
23. Wełnicki M, Gorczyca-Głowacka I, Mamcarz A, Filipiak KJ, Wożakowska-Kapłon B, Barylski M, Szymański FM, Kasprzak JD, Grabowski M, Dzida G. The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol. 2022;80(3):345-352. https://journals.viamedica.pl/polish_heart_journal/article/view/92723 (access: 2026.04.21).
24. Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, Wiese RJ, Tuttle KR, Cherney DZI. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: a post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774-785. https://doi.org/10.1016/S2213-8587(22)00243-1.
25. Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393-406. https://doi.org/10.1016/S2213-8587(22)00070-5.
26. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176. https://doi.org/10.1038/s41591-023-02672-2.
27. Mamcarz A, Momot K, Mastalerz-Migas A, Babicki M, Biesiada A, Dobrowolski P, Dzida G, Gorczyca-Głowacka I, Grabowski M, Kłoda K, Kuryłowicz A, Prejbisz A, Rozentryt P, Rydzewska G, Wyleżoł M, Ostrowska L. The role of the primary care physician in the care of patients with obesity disease – practical clinical guidelines based on the 2024 recommendations of the Polish Society for Obesity Management. Lekarz POZ. 2024;10(1):1-15. https://www.termedia.pl/Rola-lekarza-POZ-w-opiece-nad-chorym-na-chorobe-otylosciowa-praktyczne-wskazowki-postepowania-na-podstawie-zalecen-klinicznych-Polskiego-Towarzystwa-Leczenia-Otylosci-z-2024-r-,98,57222,1,0.html (access: 2026.04.21). [Polish].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Julianna Rozalia Chyl, Łukasz Kowalewski, Oliwia Barbara Gutowska, Weronika Nowak, Wiktoria Magdalena Kostuch, Agata Zimon, Maria Aleksandra Styczyńska, Olga Błażowska-Danielska, Martyna Zielnik, Alicja Jurewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 134
Number of citations: 0
